Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

NCT03143816 | Completed Phase 4 Results DMC FDA Drug

• 1 other identifier: 17-0427
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This is an investigator-initiated, prospective, randomized, multicenter, parallel, open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and time-in-range on CGM download in patients with T1D. TI is an inhaled ultra-rapid-acting insulin, approved by the FDA for use in patients with diabetes. This is a pilot, real-life study where patients will continue their routine diabetes care and use post-meal correction dosages as deemed necessary for normalizing PPBG as per the protocol. This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit. All patients will use real-time CGM (Dexcom G5®, San Diego, CA), which will be provided at the randomization visit for their day-to-day diabetes care. CGM data will be downloaded at every clinic visit on a secured computer. The data will be analyzed after the study for different primary and secondary end points. All patients will be allowed to keep the CGM after the study is over for their day-to-day diabetes care.

Conditions

Diabetes Mellitus, Type 1

Keywords

diabetes; time in range; inhaled insulin; continuous glucose monitoring; type 1 diabetes; hypoglycemia; post prandial hypergylcemia

Outcome Measures

Primary Outcomes (1)

• Change in Time in Range (%) (70-180 mg/dl) With TI on CGM

  Difference between Time in range for TI group (treatment) and for Aspart group (control)

  4 weeks

Secondary Outcomes (6)

• Change in Post-prandial Glucose Excursion (mg/dl) (1-4 Hours After Meals) With TI

  4 weeks

• Change in Glucose Variability (GV) (mg/dl) (Standard Deviation and/or Coefficient Variation)

  4 weeks

• The Area Under the Curve Calculation (AUC) (Min*mg/dl) in the PPBG and PPGE,

  0, 1, 2, 3, 4 hours post-dose at 4 weeks

• Change in HbA1c (%) in One-month Treatment

  4 weeks

• Change in Above the Target Time (%) (>180 mg/dl) on CGM

  4 weeks

Study Arms (2)

Technosphere insulin (TI, Afrezza) -Treatment arm

ACTIVE COMPARATOR

Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG ( post prandial blood glucose)

Drug: Technosphere insulin

Insulin Aspart ( Novolog) -Control arm

NO INTERVENTION

Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals.

Interventions

Technosphere insulin DRUG

This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.

Technosphere insulin (TI, Afrezza) -Treatment arm

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent before any study-related activities,
• Male or female aged 18-70 years,
• Type 1 diabetes mellitus (T1D) duration more than six months
• Treatment with multiple daily injections (MDI) for at least three months before screening visit; stable insulin dose for the last one month,
• No use of any oral anti-diabetics, any other form of insulin other than mentioned in the protocol, or any other type of injections such as glucagon-like-peptide-1 (GLP-1) analogs, pramlintide or insulin/GLP-1 analog combinations,
• A1c between 6.5 to 10%,
• Willingness to routinely collect at least two blood glucose measurements per day needed to calibrate the CGM. Beyond the calibrations, patients may use CGM for necessary action without having to confirm with fingersticks self-monitoring blood glucose (SMBG), as approved by the Food and Drug Administration (FDA),
• BMI ≤35 kg/m2,
• Ability and willingness to adhere to the protocol including clinical and phone visits and 4-week-long CGM wear,
• Using insulin glargine or insulin degludec as basal insulin,
• Able to use and understand CGM data,
• Willing to complete phone and clinic visits,
• Patients who eat three main meals in a day (breakfast, lunch, and dinner),
• Patients who use insulin-carb ratio for bolus,
• Ability to speak, read, and write English, and

You may not qualify if:

• Use of any other diabetic medication other than allowed in the protocol,
• Pregnant or intention to become pregnant during the study, or not using adequate birth control methods,
• Severe unexplained hypoglycemia requiring emergency treatment in the previous three months,
• Use of systemic or inhaled corticosteroids,
• History of hemoglobinopathies,
• Diagnosis of anemia,
• Post-renal transplantation, currently undergoing dialysis, creatinine \>2.0 mg/dl or a calculated creatinine clearance of \<50 mL/min,
• Advanced or unstable retinopathy needing laser procedure or vitrectomy,
• History of pancreatitis,
• Extensive skin changes/diseases that inhibit wearing a sensor on normal skin,
• Known allergy to adhesives,
• Known allergy to study medication,
• Participation in another investigational study protocol within 30 days before enrollment,
• Known chronic obstructive pulmonary disease, pulmonary hypertension, asthma, pulmonary fibrosis, or any chronic pulmonary infection, or any systemic disease that primarily affects the lungs. History of any pulmonary nodule will be excluded to participate in the study,
• Active smokers,

Sponsors & Collaborators

• University of Colorado, Denver: lead
• Atlanta Diabetes Associates: collaborator
• University of Southern California: collaborator
• Rainier Clinical Research Center: collaborator
• Mannkind Corporation: collaborator

Study Sites (1)

Barbara Davis Center

Aurora, Colorado, 80045, United States

Location

Related Publications (8)

• 1. Rathbone M, Hadgraft J, Roberts M, Lane M, Leone-Bay A, Grant M. Technosphere/insulin: mimicking endogenous insulin release. In Modified-Release Drug Delivery Technology. Vol. 2, 2nd ed. Rathbone M, Hadgraft J, Roberts M, Lane M, Eds. New York, Informa Healthcare USA, Inc., 2008, p. 673-679

  BACKGROUND

• Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S65-72. doi: 10.1089/dia.2007.0212.

  PMID: 17563306 BACKGROUND

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf, April 2017

  BACKGROUND

• Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB; Affinity 1 Study Group. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial. Diabetes Care. 2015 Dec;38(12):2266-73. doi: 10.2337/dc15-0075. Epub 2015 Jul 15.

  PMID: 26180109 BACKGROUND

• Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, Petrucci RE, Boss AH, Richardson PC. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010 Jun 26;375(9733):2244-53. doi: 10.1016/S0140-6736(10)60632-0.

  PMID: 20609970 BACKGROUND

• Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care. 2005 Jul;28(7):1630-5. doi: 10.2337/diacare.28.7.1630.

  PMID: 15983312 BACKGROUND

• Garg SK, Kelly W, Freson B, Ritchie P. Treat-to-target technosphere insulin study in adult subjects with type 1 diabetes. Poster presented at American Diabetes Association 2011 annual meeting.

  BACKGROUND

• Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 Oct;20(10):639-647. doi: 10.1089/dia.2018.0200. Epub 2018 Sep 15.

  PMID: 30207748 DERIVED

MeSH Terms

Conditions

Diabetes Mellitus, Type 1; Diabetes Mellitus; Hypoglycemia

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Results Point of Contact

• Title: Satish Garg MD
• Organization: Barbara Davis Center for Diabetes, University of Colorado

satish.garg@ucdenver.edu

3037246713

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2017
• First Posted: May 8, 2017
• Study Start: September 30, 2017
• Primary Completion: December 15, 2017
• Study Completion: January 31, 2018
• Last Updated: February 22, 2022
• Results First Posted: February 22, 2022

Record last verified: 2022-01

Data Sharing

• IPD Sharing: Will share

Locations

US (1)